NCT03040427

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: The Cleveland Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 95 Years
• Healthy volunteers: Not accepted

Summary

The investigators postulate that F-18 florbetapir will show improved detection of cardiac amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.

Detailed description

F-18 florbetapir is currently used for the early detection of brain amyloid (Alzheimer's disease). The hypothesis is that F-18 florbetapir will detect amyloid deposition in myocardium prior to current non-invasive diagnostic measures, particular electrocardiography with strain and technetium pyrophosphate scintigraphy. The investigators intend to use F-18 florbetapir and assess its correlation between standard non-invasive diagnostic modalities.

Conditions

• Cardiac Amyloidosis

Interventions

Type	Name	Description
DRUG	F-18 florbetapir	Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).

Timeline

• Start date: 2017-01-01
• Primary completion: 2019-08-21
• Completion: 2019-08-21
• First posted: 2017-02-02
• Last updated: 2021-07-27
• Results posted: 2021-07-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study